Dexamethasone Sensitizes Cancer Stem Cells to Gemcitabine and 5-Fluorouracil by Increasing Reactive Oxygen Species Production through NRF2 Reduction
Abstract
:1. Introduction
2. Materials and Methods
2.1. Antibodies and Drugs
2.2. Cell Culture
2.3. siRNA
2.4. Cell Number and Viability
2.5. Quantification of Intracellular ROS
2.6. Western Blot
2.7. Quantification of Glutathione
2.8. Statistical Analysis
3. Results
3.1. Sensitization of CSLCs to Gemcitabine and 5-FU Is Induced by Dexamethasone and Reversed by N-Acetyl-Cysteine
3.2. Dexamethasone Promotes the Gemcitabine- and 5-FU-Induced Increase in ROS Levels in CSLCs
3.3. Dexamethasone Suppresses NRF2 Expression in CSLCs
3.4. Effects of Dexamethasone on Colorectal Cancer and Ovarian CSLCs
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer statistics, 2021. CA Cancer J. Clin. 2021, 1, 7–33. [Google Scholar] [CrossRef]
- Russano, M.; Napolitano, A.; Ribelli, G.; Iuliani, M.; Simonetti, S.; Citarella, F.; Pantano, F.; Dell'Aquila, E.; Anesi, C.; Silvestris, N.; et al. Liquid biopsy and tumor heterogeneity in metastatic solid tumors: The potentiality of blood samples. J. Exp. Clin. Cancer Res. 2020, 39, 95. [Google Scholar] [CrossRef]
- Agnoletto, C.; Corrà, F.; Minotti, L.; Baldassari, F.; Crudele, F.; Cook, W.J.J.; Di Leva, G.; D’Adamo, A.P.; Gasparini, P.; Volinia, S. Heterogeneity in Circulating Tumor Cells: The Relevance of the Stem-Cell Subset. Cancers 2019, 11, 483. [Google Scholar] [CrossRef] [Green Version]
- Malik, B.; Nie, D. Cancer stem cells and resistance to chemo and radio therapy. Front. Biosci. 2012, 4, 2142–2149. [Google Scholar] [CrossRef]
- Reya, T.; Morrison, S.J.; Clarke, M.F.; Weissman, I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 6859, 105–111. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yu, Y.; Ramena, G.; Elble, R.C. The role of cancer stem cells in relapse of solid tumors. Front. Biosci. 2012, 4, 1528–1541. [Google Scholar] [CrossRef]
- Yu, Z.; Pestell, T.G.; Lisanti, M.P.; Pestell, R.G. Cancer stem cells. Int. J. Biochem. Cell Biol. 2012, 12, 2144–2151. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Maugeri, M.; Vigneri, P.; De Maria, R. Cancer Stem Cells and Chemosensitivity. Clin. Cancer Res. 2011, 17, 4942–4947. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Batlle, E.; Clevers, H. Cancer stem cells revisited. Nat. Med. 2017, 23, 1124–1134. [Google Scholar] [CrossRef] [PubMed]
- Kahroba, H.; Shirmohamadi, M.; Hejazi, M.S.; Samadi, N. The Role of Nrf2 signaling in cancer stem cells: From stemness and self-renewal to tumorigenesis and chemoresistance. Life Sci. 2019, 239, 116986. [Google Scholar] [CrossRef]
- Langedijk, J.; Mantel-Teeuwisse, A.K.; Slijkerman, D.S.; Schutjens, M.-H.D. Drug repositioning and repurposing: Terminology and definitions in literature. Drug Discov. Today 2015, 20, 1027–1034. [Google Scholar] [CrossRef] [PubMed]
- De Oliveira, G.S., Jr.; Castro-Alves, L.J.; Ahmad, S.; Kendall, M.C.; McCarthy, R.J. Dexamethasone to prevent postoperative nausea and vomiting: An updated meta-analysis of randomized controlled trials. Anesth. Analg. 2013, 1, 58–74. [Google Scholar] [CrossRef] [Green Version]
- Apfel, C.C.; Korttila, K.; Abdalla, M.; Kerger, H.; Turan, A.; Vedder, I.; Zernak, C.; Danner, K.; Jokela, R.; Pocock, S.J.; et al. A Factorial Trial of Six Interventions for the Prevention of Postoperative Nausea and Vomiting. N. Engl. J. Med. 2004, 350, 2441–2451. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhou, Y.; Zhou, Y.; Wang, K.; Li, T.; Yang, M.; Wang, R.; Chen, Y.; Cao, M.; Hu, R. Flumethasone enhances the efficacy of chemotherapeutic drugs in lung cancer by inhibiting Nrf2 signaling pathway. Cancer Lett. 2020, 474, 94–105. [Google Scholar] [CrossRef]
- He, J.; Zhou, J.; Yang, W.; Zhou, Q.; Liang, X.; Pang, X.; Li, J.; Pan, F.; Liang, H. Dexamethasone affects cell growth/apoptosis/chemosensitivity of colon cancer via glucocorticoid receptor α/nf-κb. Oncotarget 2017, 40, 67670–67683. [Google Scholar] [CrossRef] [Green Version]
- Wang, H.; Wang, Y.; Rayburn, E.R.; Hill, D.L.; Rinehart, J.J.; Zhang, R. Dexamethasone as a chemosensitizer for breast cancer chemotherapy: Potentiation of the antitumor activity of adriamycin, modulation of cytokine expression, and pharmacokinetics. Int. J. Oncol. 2007, 30, 947–953. [Google Scholar] [CrossRef] [PubMed]
- Gong, J.-H.; Zheng, Y.-B.; Zhang, M.-R.; Wang, Y.-X.; Yang, S.-Q.; Wang, R.-H.; Miao, Q.-F.; Liu, X.-J.; Zhen, Y.-S. Dexamethasone enhances the antitumor efficacy of Gemcitabine by glucocorticoid receptor signaling. Cancer Biol. Ther. 2020, 21, 332–343. [Google Scholar] [CrossRef] [PubMed]
- Suzuki, S.; Okada, M.; Sanomachi, T.; Togashi, K.; Seino, S.; Sato, A.; Yamamoto, M.; Kitanaka, C. Therapeutic targeting of pancreatic cancer stem cells by dexamethasone modulation of the MKP-1–JNK axis. J. Biol. Chem. 2020, 295, 18328–18342. [Google Scholar] [CrossRef]
- Okada, M.; Shibuya, K.; Sato, A.; Seino, S.; Suzuki, S.; Seino, M.; Kitanaka, C. Targeting the K-Ras—JNK axis eliminates cancer stem-like cells and prevents pancreatic tumor formation. Oncotarget 2014, 5, 5100–5112. [Google Scholar] [CrossRef] [Green Version]
- Kuramoto, K.; Yamamoto, M.; Suzuki, S.; Togashi, K.; Sanomachi, T.; Kitanaka, C.; Okada, M. Inhibition of the Lipid Droplet–Peroxisome Proliferator-Activated Receptor α Axis Suppresses Cancer Stem Cell Properties. Genes 2021, 12, 99. [Google Scholar] [CrossRef] [PubMed]
- Seino, M.; Okada, M.; Shibuya, K.; Seino, S.; Suzuki, S.; Ohta, T.; Kurachi, H.; Kitanaka, C. Requirement of jnk signaling for self-renewal and tumor-initiating capacity of ovarian cancer stem cells. Anticancer Res. 2014, 9, 4723–4731. [Google Scholar]
- Yamada, H.; Yoshida, T.; Sakamoto, H.; Terada, M.; Sugimura, T. Establishment of a human pancreatic adenocarcinoma cell line (PSN-1) with amplifications of both c-myc and activated c-Ki-ras by a point mutation. Biochem. Biophys. Res. Commun. 1986, 140, 167–173. [Google Scholar] [CrossRef]
- Hamilton, T.C.; Winker, M.A.; Louie, K.G.; Batist, G.; Behrens, B.C.; Tsuruo, T.; Grotzinger, K.R.; McKoy, W.M.; Young, R.C.; Ozols, R.F. Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem. Pharmacol. 1985, 34, 2583–2586. [Google Scholar] [CrossRef]
- Ohta, T.; Ohmichi, M.; Shibuya, T.; Takahashi, T.; Tsutsumi, S.; Takahashi, K.; Kurachi, H. Gefitinib (ZD1839) increases the efficacy of cisplatin in ovarian cancer cells. Cancer Biol. Ther. 2012, 13, 408–416. [Google Scholar] [CrossRef] [Green Version]
- Sueyoshi, M.; Fukunaga, M.; Mei, M.; Nakajima, A.; Tanaka, G.; Murase, T.; Narita, Y.; Hirata, S.; Kadowaki, D. Effects of lactulose on renal function and gut microbiota in adenine-induced chronic kidney disease rats. Clin. Exp. Nephrol. 2019, 23, 908–919. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Suzuki, S.; Okada, M.; Shibuya, K.; Seino, M.; Sato, A.; Takeda, H.; Seino, S.; Yoshioka, T.; Kitanaka, C. JNK suppression of chemotherapeutic agents-induced ROS confers chemoresistance on pancreatic cancer stem cells. Oncotarget 2014, 6, 458–470. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Motohashi, H.; Yamamoto, M. Nrf2–Keap1 defines a physiologically important stress response mechanism. Trends Mol. Med. 2004, 10, 549–557. [Google Scholar] [CrossRef] [PubMed]
- Hwang, P.M.; Bunz, F.; Yu, J.; Rago, C.; Chan, T.A.; Murphy, M.P.; Kelso, G.F.; Smith, R.A.; Kinzler, K.W.; Vogelstein, B. Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells. Nat. Med. 2001, 10, 1111–1117. [Google Scholar] [CrossRef] [Green Version]
- Maehara, S.-I.; Tanaka, S.; Shimada, M.; Shirabe, K.; Saito, Y.; Takahashi, K.; Maehara, Y. Selenoprotein P, as a predictor for evaluating gemcitabine resistance in human pancreatic cancer cells. Int. J. Cancer 2004, 112, 184–189. [Google Scholar] [CrossRef]
- Almeida, M.; Han, L.; Ambrogini, E.; Weinstein, R.S.; Manolagas, S.C. Glucocorticoids and Tumor Necrosis Factor α Increase Oxidative Stress and Suppress Wnt Protein Signaling in Osteoblasts. J. Biol. Chem. 2011, 286, 44326–44335. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhang, S.; Li, D.; Yang, J.-Y.; Yan, T.-B. Plumbagin protects against glucocorticoid-induced osteoporosis through Nrf-2 pathway. Cell Stress Chaperon. 2015, 20, 621–629. [Google Scholar] [CrossRef] [Green Version]
- Alam, M.; Okazaki, K.; Nguyen, L.T.T.; Ota, N.; Kitamura, H.; Murakami, S.; Shima, H.; Igarashi, K.; Sekine, H.; Motohashi, H. Glucocorticoid receptor signaling represses the antioxidant response by inhibiting histone acetylation mediated by the transcriptional activator NRF2. J. Biol. Chem. 2017, 292, 7519–7530. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schwartz, J.R. Dexamethasone premedication for prophylaxis of taxane toxicities: Can the doses be reduced when paclitaxel or docetaxel are given weekly? J. Oncol. Pharm. Pract. 2012, 2, 250–256. [Google Scholar] [CrossRef]
- Kaal, E.C.; Vecht, C.J. The management of brain edema in brain tumors. Curr. Opin. Oncol. 2004, 16, 593–600. [Google Scholar] [CrossRef] [PubMed]
- Walsh, D.; Davis, M.; Ripamonti, C.; Bruera, E.; Davies, A.; Molassiotis, A. 2016 updated mascc/esmo consensus recommendations: Management of nausea and vomiting in advanced cancer. Support Care Cancer 2017, 1, 333–340. [Google Scholar] [CrossRef]
- Jiang, D.M.; Chan, K.K.W.; Jang, R.W.; Booth, C.; Liu, G.; Amir, E.; Mason, R.; Everest, L.; Elimova, E. Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerations. Cancer Med. 2019, 8, 1584–1593. [Google Scholar] [CrossRef] [PubMed]
- Vardy, J.; Chiew, K.; Galica, J.; Pond, G.R.; Tannock, I.F. Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br. J. Cancer 2006, 94, 1011–1015. [Google Scholar] [CrossRef] [PubMed]
- Weinstein, R.S. Glucocorticoid-Induced Bone Disease. N. Engl. J. Med. 2011, 365, 62–70. [Google Scholar] [CrossRef]
- den Uyl, D.; Bultink, I.E.; Lems, W.F. Advances in glucocorticoid-induced osteoporosis. Curr. Rheumatol. Rep. 2011, 3, 233–240. [Google Scholar] [CrossRef] [Green Version]
- Celio, L.; Bonizzoni, E.; Zattarin, E.; Codega, P.; De Braud, F.; Aapro, M. Impact of dexamethasone-sparing regimens on delayed nausea caused by moderately or highly emetogenic chemotherapy: A meta-analysis of randomised evidence. BMC Cancer 2019, 19, 1–13. [Google Scholar] [CrossRef] [Green Version]
- Gu, Y.L.; Xie, J.M.; Ren, J.; Cao, H.; Wei, J.R.; Chen, C.; Shao, L.N.; Jiang, G.Q. Dexamethasone-sparing regimen is an effective and safe alternative in overall antiemetic protection: A systematic review and meta-analysis. Medicine 2019, 98, e17364. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Suzuki, S.; Yamamoto, M.; Sanomachi, T.; Togashi, K.; Sugai, A.; Seino, S.; Yoshioka, T.; Okada, M.; Kitanaka, C. Dexamethasone Sensitizes Cancer Stem Cells to Gemcitabine and 5-Fluorouracil by Increasing Reactive Oxygen Species Production through NRF2 Reduction. Life 2021, 11, 885. https://doi.org/10.3390/life11090885
Suzuki S, Yamamoto M, Sanomachi T, Togashi K, Sugai A, Seino S, Yoshioka T, Okada M, Kitanaka C. Dexamethasone Sensitizes Cancer Stem Cells to Gemcitabine and 5-Fluorouracil by Increasing Reactive Oxygen Species Production through NRF2 Reduction. Life. 2021; 11(9):885. https://doi.org/10.3390/life11090885
Chicago/Turabian StyleSuzuki, Shuhei, Masahiro Yamamoto, Tomomi Sanomachi, Keita Togashi, Asuka Sugai, Shizuka Seino, Takashi Yoshioka, Masashi Okada, and Chifumi Kitanaka. 2021. "Dexamethasone Sensitizes Cancer Stem Cells to Gemcitabine and 5-Fluorouracil by Increasing Reactive Oxygen Species Production through NRF2 Reduction" Life 11, no. 9: 885. https://doi.org/10.3390/life11090885